CN105497868B - 一种林蛙油水溶性蛋白口服液及其制备方法 - Google Patents
一种林蛙油水溶性蛋白口服液及其制备方法 Download PDFInfo
- Publication number
- CN105497868B CN105497868B CN201510985270.7A CN201510985270A CN105497868B CN 105497868 B CN105497868 B CN 105497868B CN 201510985270 A CN201510985270 A CN 201510985270A CN 105497868 B CN105497868 B CN 105497868B
- Authority
- CN
- China
- Prior art keywords
- water
- oviductus ranae
- syrup
- solubility
- solubility protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000003101 oviduct Anatomy 0.000 title claims abstract description 83
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 76
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 76
- 229940100688 oral solution Drugs 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 29
- 239000003755 preservative agent Substances 0.000 claims abstract description 14
- 230000002335 preservative effect Effects 0.000 claims abstract description 14
- 239000007788 liquid Substances 0.000 claims abstract description 13
- 239000008213 purified water Substances 0.000 claims abstract description 9
- 238000004090 dissolution Methods 0.000 claims abstract description 4
- 230000001954 sterilising effect Effects 0.000 claims abstract description 4
- 238000007789 sealing Methods 0.000 claims abstract description 3
- 235000020357 syrup Nutrition 0.000 claims description 36
- 239000006188 syrup Substances 0.000 claims description 36
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 22
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 22
- 235000010447 xylitol Nutrition 0.000 claims description 22
- 239000000811 xylitol Substances 0.000 claims description 22
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 22
- 229960002675 xylitol Drugs 0.000 claims description 22
- 241000202807 Glycyrrhiza Species 0.000 claims description 18
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 claims description 18
- 230000003078 antioxidant effect Effects 0.000 claims description 17
- 239000003963 antioxidant agent Substances 0.000 claims description 15
- 239000006228 supernatant Substances 0.000 claims description 13
- 239000004376 Sucralose Substances 0.000 claims description 12
- 235000020426 cherry syrup Nutrition 0.000 claims description 12
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 12
- 235000019408 sucralose Nutrition 0.000 claims description 12
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 11
- 235000010241 potassium sorbate Nutrition 0.000 claims description 11
- 239000004302 potassium sorbate Substances 0.000 claims description 11
- 229940069338 potassium sorbate Drugs 0.000 claims description 11
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 10
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 10
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 10
- 229930006000 Sucrose Natural products 0.000 claims description 10
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 10
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 10
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 10
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 10
- 229940013618 stevioside Drugs 0.000 claims description 10
- 235000019202 steviosides Nutrition 0.000 claims description 10
- 239000005720 sucrose Substances 0.000 claims description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 9
- 239000012153 distilled water Substances 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 229920005989 resin Polymers 0.000 claims description 8
- 239000011347 resin Substances 0.000 claims description 8
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 7
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- 238000000502 dialysis Methods 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 230000001376 precipitating effect Effects 0.000 claims description 5
- BCZXFFBUYPCTSJ-UHFFFAOYSA-L Calcium propionate Chemical compound [Ca+2].CCC([O-])=O.CCC([O-])=O BCZXFFBUYPCTSJ-UHFFFAOYSA-L 0.000 claims description 3
- 241000191896 Rana sylvatica Species 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 235000010331 calcium propionate Nutrition 0.000 claims description 3
- 239000004330 calcium propionate Substances 0.000 claims description 3
- 229920001429 chelating resin Polymers 0.000 claims description 3
- 238000002242 deionisation method Methods 0.000 claims description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 3
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 235000013376 functional food Nutrition 0.000 claims description 3
- 239000004519 grease Substances 0.000 claims description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 3
- 229960002216 methylparaben Drugs 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 238000003825 pressing Methods 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 239000002002 slurry Substances 0.000 claims description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 3
- 235000010234 sodium benzoate Nutrition 0.000 claims description 3
- 239000004299 sodium benzoate Substances 0.000 claims description 3
- 229960003885 sodium benzoate Drugs 0.000 claims description 3
- 235000010199 sorbic acid Nutrition 0.000 claims description 3
- 239000004334 sorbic acid Substances 0.000 claims description 3
- 229940075582 sorbic acid Drugs 0.000 claims description 3
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 3
- 238000012870 ammonium sulfate precipitation Methods 0.000 claims description 2
- 239000003480 eluent Substances 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 abstract description 24
- 102000019197 Superoxide Dismutase Human genes 0.000 abstract description 12
- 108010012715 Superoxide dismutase Proteins 0.000 abstract description 12
- 229960003180 glutathione Drugs 0.000 abstract description 12
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 abstract description 11
- 230000003647 oxidation Effects 0.000 abstract description 9
- 238000007254 oxidation reaction Methods 0.000 abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 8
- 241000270930 Rana japonica Species 0.000 abstract description 8
- 230000002829 reductive effect Effects 0.000 abstract description 5
- 108010024636 Glutathione Proteins 0.000 abstract description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract description 3
- 238000002156 mixing Methods 0.000 abstract description 3
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 2
- 235000006708 antioxidants Nutrition 0.000 description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 7
- 230000001590 oxidative effect Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 5
- 229930003268 Vitamin C Natural products 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 235000019154 vitamin C Nutrition 0.000 description 5
- 239000011718 vitamin C Substances 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 238000013329 compounding Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 229960004365 benzoic acid Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 235000007686 potassium Nutrition 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000269435 Rana <genus> Species 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003260 anti-sepsis Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000012683 free radical ring-opening polymerization Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- -1 phosphatide Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/65—Amphibians, e.g. toads, frogs, salamanders or newts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种林蛙油水溶性蛋白口服液及其制备方法。配方为每1000mL口服液含有林蛙油水溶性蛋白100~50g,矫味剂12.5~5g,防腐剂1~2g。制备方法为林蛙油水溶性蛋白加入到纯化水中,180~220 r/min搅拌至溶解,控制温度10~30℃,再分别加入矫味剂、防腐剂于180~220 r/min转速下搅拌均匀后,罐装瞬时灭菌,装瓶、封口。本发明所提供的林蛙油口服液在乙醇氧化损伤模型鼠体内具有显著的抗氧化作用,可降低丙二醛(MDA)和蛋白质羰基(PC)含量,升高超氧化物歧化酶(SOD)活力及谷胱甘肽(GSH)含量,最佳有效剂量为10 mL/(kg.d),人体推荐剂量为77 mL/d。
Description
技术领域
本发明属于保健品领域,具体为一种林蛙油水溶性蛋白口服液及其制备方法,该林蛙油口服液具有抗氧化的保健功效。
背景技术
对机体而言,活性氧自由基是一把“双刃剑”,其在生理浓度时广泛参与细胞的信号转导和生命过程,过量时又能引起线粒体氧化应激,从而导致衰老及相关疾病的发生。如何保持细胞内的氧化与抗氧化平衡(氧化还原平衡),既不过度氧化损伤,也不过度抗氧化而影响正常的信号转导,这对健康极为重要。大量研究已证实,人体本身就具有清除多余自由基的能力,这主要靠内源性自由基清除系统,包括超氧化物歧化酶(SOD)、过氧化氢酶、谷胱甘肽过氧化酶等一些酶和维生素C、维生素E、还原性谷胱甘肽等一些抗氧剂。酶类物质可以使体内的活性氧自由基变为活性较低的物质,从而削弱它们对机体的攻击力。酶的防御作用仅限于细胞内,而抗氧化剂有些作用于细胞膜,有些则在细胞外就可起到防御作用。因此,外源性补充抗氧化剂对于维持正常生理功能及相关疾病的辅助治疗具有积极作用。
基于化学合成的人工抗氧化剂存在毒性大、体内蓄积、不宜长期服用等缺点,相比之下,源于天然产物的抗氧化剂毒性轻微、效果显著、更易耐受,已成为抗氧化市场的主流产品。
林蛙油(Oviductus rana)是我国名贵的中药材,富含高达 50% 以上的蛋白质,还含有丰富的糖类、脂肪、磷脂、维生素、脂肪酸、矿物质及激素等营养成分。《中药大词典》记载:林蛙油具有独特的“补肾益精、润肺养阴”之功效,用于治疗“病后、产后虚弱、肺痨、咳嗽、吐血、盗汗”等症;《中国药物学》记载:蛤蟆油是“润肺、生津、补虚的身体增强剂,是身体衰弱的滋补佳品”。我国林蛙资源丰富,现有技术中已有林蛙油食品制作或林蛙油酶水解肽入药的技术,但对于我国林蛙油资源仍然存在广阔的开发空间,有着巨大的开发价值和市场前景。对于林蛙油如何有效利用,如何开发其各种成分的最佳用途,探索出最佳服用剂量,成为林蛙油产品研究的关键问题。
发明内容
本发明目的在于提供一种林蛙油水溶性蛋白口服液及其制备方法,以林蛙油水溶性蛋白为活性成分,降低脂溶性成分所引起的不良反应,利于机体吸收,增强保健功能。本发明的目的是由以下技术方案实现的:
一种林蛙油水溶性蛋白口服液,每1000mL所述口服液含有以下重量的各组分:林蛙油水溶性蛋白100~50g,矫味剂12.5~5g,防腐剂1~2g。
进一步的,所述林蛙油水溶性蛋白的制备包括:1)林蛙油水溶性总蛋白的提取和2)林蛙油水溶性蛋白的纯化;所述步骤1)林蛙油水溶性总蛋白的提取的具体步骤为:取林蛙油,加入 pH 6.0 ~ 7.0 的5~10倍量水溶液中搅拌提取3~5 h,压滤,残渣重复提取,合并多次提取液,进行第一次离心处理,取上清液,经中空纤维柱膜过滤,滤液用65~70%硫酸铵沉淀6~12 h,对沉淀进行第二次离心处理,将沉淀置0~10℃蒸馏水透析,至透析液没有沉淀产生,对透析液进行第三次离心处理,得含有林蛙油水溶性总蛋白的上清液。
进一步的,所述步骤2)林蛙油水溶性蛋白的纯化的具体步骤为:将步骤1)中所得含有林蛙油水溶性总蛋白的上清液中加入Amberlite CG50树脂,于20~25℃搅拌吸附2~5h,倾去上层液体,所述树脂用蒸馏水洗涤后上柱,用0.2-0.4 mol/L磷酸氢二钾-0.1-0.3mol/L氯化钾混合液洗脱,流速8 mL/10 min,洗脱液用蒸馏水透析去离子后真空冷冻干燥,得纯化后的林蛙油水溶性蛋白。
进一步的,所述矫味剂为蔗糖、木糖醇、三氯蔗糖、橙皮糖浆、枸橼糖浆、樱桃糖浆、甘草糖浆、桂皮糖浆、甜菊苷其中一种或几种的混合物。
进一步的,所述矫味剂为木糖醇或木糖醇与蔗糖、三氯蔗糖、橙皮糖浆、枸橼糖浆、樱桃糖浆、甘草糖浆、桂皮糖浆、甜菊苷中其中一种或几种混合物。
进一步的,所述矫味剂为甘草糖浆或甘草糖浆与木糖醇、蔗糖、三氯蔗糖、橙皮糖浆、枸橼糖浆、樱桃糖浆、桂皮糖浆、甜菊苷中其中一种或几种混合物。
进一步的,所述防腐剂为苯甲酸、苯甲酸钠、山梨酸、山梨酸钾、丙酸钙、尼泊金甲酯、尼泊金乙酯中一种或两种复配。
一种林蛙油水溶性蛋白口服液的制备方法,每1000mL所述口服液含有以下重量的各组分:林蛙油水溶性蛋白100~50g,矫味剂12.5~5g,防腐剂1~2g;
具体制备步骤为:按上述组分的重量,取林蛙油水溶性蛋白加入到纯化水中,180~220 r/min 搅拌至溶解,控制温度10~30℃,再分别加入矫味剂、防腐剂于180~220 r/min转速下搅拌均匀后,罐装瞬时灭菌,装瓶、封口。
所述林蛙油水溶性蛋白口服液在制备抗氧化保健食品中的应用。
所述林蛙油水溶性蛋白口服液的使用方法,所述口服液的服用剂量为体重120kg成人7mL/d。
本发明的有益效果:
1)本发明提供的林蛙油口服液以抗氧化活性最强的水溶性蛋白为活性成分,不仅可提高保健功效,同时能降低脂溶性成分所引起的不良反应。
2)简化口服液配方,除林蛙油水溶性蛋白外,仅加入矫味剂和防腐剂,有效避免多种活性成分配伍所引起的不良相互作用,更有利于单一组分功效的发挥。
3)同时,由于活性成分水溶性良好,有利于口服液稳定性的提高,便于制剂加工、储存、运输,具有产业化开发价值。
4)在乙醇诱导氧化损伤模型小鼠体内,本发明提供的林蛙油水溶性蛋白口服液能显著降低脂质氧化产物丙二醛(MDA)和蛋白质羰基(PC)的含量;升高抗氧化酶超氧化物歧化酶(SOD)活力和谷胱甘肽(GSH)含量,显示较为理想的抗氧化作用。
具体实施方式
实施例1
一种林蛙油水溶性蛋白口服液,每1000mL所述口服液含有以下重量的各组分:林蛙油水溶性蛋白100~50g,矫味剂12.5~5g,防腐剂1~2g。
其中的林蛙油可购买市售产品
林蛙油水溶性蛋白的制备包括:1)林蛙油水溶性总蛋白的提取和2)林蛙油水溶性蛋白的纯化;步骤1)林蛙油水溶性总蛋白的提取的具体步骤为:取干燥的林蛙油,加入 pH6.0 ~ 7.0 的5~10倍量(重量比)水溶液中搅拌提取3~5 h(优选3h),压滤,残渣重复提取(2次),合并多次提取液,进行第一次离心处理,4500 r/min离心5~10 min,取上清液,经中空纤维柱膜过滤,滤液用65~70%(优选65%)硫酸铵沉淀6~12 h(优选6h),沉淀进行第二次离心处理,4500 r/min离心5~10 min,将沉淀置0~10℃(优选4℃)蒸馏水透析,用1% BaCl2检验透析液,至透析液没有沉淀产生,将透析液进行第三次离心处理,4500 r/min离心5 min,得含有林蛙油水溶性总蛋白的上清液。
步骤2)林蛙油水溶性蛋白的纯化的具体步骤为:将步骤1)中所得含有林蛙油水溶性总蛋白的上清液中加入过处理的Amberlite CG50树脂(上清液与树脂质量的质量比值为:1:10~1:15),于20~25℃搅拌吸附2~5 h,倾去上层液体,所述树脂用蒸馏水洗涤3次后上柱,用0.2~0.4 mol/L磷酸氢二钾-0.1~0.3 mol/L氯化钾混合液洗脱,流速8 mL/10 min,洗脱液用蒸馏水透析去离子后真空冷冻干燥,得纯化后的林蛙油水溶性蛋白。考马斯亮蓝法测定林蛙油水溶性蛋白质含量为95~97℅;凝胶层析法测定其分子量为20 KDa~13 KDa。树脂处理方法为:取干Amoerlite CG50树脂,水漂洗后加5倍体积l mol/LNaOH搅拌2h,水洗至中性。加5倍体积l mol/L HC1处理2h,水洗至中性,再用pH 4.5 0.1mol/L醋酸缓冲液平衡过夜。
矫味剂为蔗糖、木糖醇、三氯蔗糖、橙皮糖浆、枸橼糖浆、樱桃糖浆、甘草糖浆、桂皮糖浆、甜菊苷其中一种或几种的混合物。
矫味剂的一种优选方案为木糖醇或木糖醇与蔗糖、三氯蔗糖、橙皮糖浆、枸橼糖浆、樱桃糖浆、甘草糖浆、桂皮糖浆、甜菊苷中其中一种或几种混合物。木糖醇不但甜度高,且不参与人体能量代谢,适合糖尿病患者食用,而且与本发明中的林蛙油水溶性蛋白结合可以有效掩盖其特有的腥味。三氯蔗糖的甜度约是蔗糖的600倍,以木糖醇混合少量三氯蔗糖做为矫味剂可以完全遮盖林蛙油水溶性蛋白的腥味,口感更佳。推荐添加量重量比为林蛙油水溶性蛋白:木糖醇:三氯蔗糖=100~50:10~4.5:2.5~0.5。
矫味剂的另一种优选方案为甘草糖浆或甘草糖浆与木糖醇、蔗糖、三氯蔗糖、橙皮糖浆、枸橼糖浆、樱桃糖浆、桂皮糖浆、甜菊苷中其中一种或几种混合物。甘草糖浆中富含的甘草次酸是一种植物源抗氧化剂,可与林蛙油水溶性蛋白发挥协同作用,其口感先甜后甘,可弥补木糖醇单一的甜味,木糖醇和甘草糖浆复配使口服液口感更佳,其中优选的添加重量比为林蛙油水溶性蛋白:木糖醇:甘草糖浆 = 100~50:7~3.5:6~2
防腐剂为苯甲酸、苯甲酸钠、山梨酸、山梨酸钾、丙酸钙、尼泊金甲酯、尼泊金乙酯中一种或两种复配。防腐剂优选山梨酸钾、尼泊金乙酯或山梨酸钾和尼泊金乙酯复配,山梨酸钾微酸,除起到防腐作用外,还可以起到矫味作用,使口服液酸甜可口,与尼泊金乙酯复配可减少其用量,发挥协同作用,优选的添加量重量比为林蛙油水溶性蛋白:山梨酸钾 =30~25:1;林蛙油水溶性蛋白:尼泊金乙酯 = 55~45:1;林蛙油水溶性蛋白:山梨酸钾:尼泊金乙酯 = 90~110:1:1。
林蛙油水溶性蛋白口服液的制备方法,具体制备步骤为:按上述组分的重量,取林蛙油水溶性蛋白加入到纯化水中,180~220 r/min 搅拌至溶解,控制温度10~30℃,再分别加入矫味剂、防腐剂于180~220 r/min转速下搅拌均匀后,罐装瞬时灭菌,装瓶、封口。
林蛙油水溶性蛋白口服液可应用于在制备抗氧化保健食品中。
本发明林蛙油水溶性蛋白口服液在乙醇诱导氧化损伤模型鼠体内抗氧化的最佳剂量为10 mL/(kg.d),换算为人体推荐剂量为77 mL/d。
实施例2
在实施例1的基础上进一步改进。
所述林蛙油水溶性蛋白口服液的各组分重量份数比为:林蛙油水溶性蛋白 50 g,木糖醇 12.5 g, 山梨酸钾 2 g, 纯化水 1000 mL。
实施例3
在实施例1的基础上进一步改进。
所述林蛙油水溶性蛋白口服液的各组分重量份数比为:
林蛙油水溶性蛋白 50 g, 木糖醇8 g 三氯蔗糖 1.5 g, 尼泊金乙酯 1 g, 纯化水 1000 mL。
实施例4
在实施例1的基础上进一步改进。
所述林蛙油水溶性蛋白口服液的各组分重量份数比为:
林蛙油水溶性蛋白 50 g, 甘草糖浆 7.5 g, 山梨酸钾 2 g, 纯化水 1000 mL。
实施例5
在实施例1的基础上进一步改进。
所述林蛙油水溶性蛋白口服液的各组分重量份数比为:
林蛙油水溶性蛋白 50 g, 甘草糖浆 5 g, 樱桃糖浆 2.5g, 山梨酸钾 0.5 g,尼泊金乙酯 0.5 g, 纯化水 1000 mL。
实施例6
在实施例1的基础上进一步改进。
所述林蛙油水溶性蛋白口服液的各组分重量份数比为:
林蛙油水溶性蛋白 50 g, 木糖醇2.5 g, 甘草糖浆2.5 g, 樱桃糖浆1 g, 山梨酸钾2 g, 纯化水 1000 mL。
实施例7
在实施例1的基础上进一步改进。
林蛙油水溶性蛋白 50 g,木糖醇2.5 g,甘草糖浆2.5 g,樱桃糖浆1 g,桂皮糖浆0.5 g,甜菊苷0.5 g,山梨酸钾1 g,尼泊金乙酯(或尼泊金甲酯)1g, 纯化水 1000 mL。
本发明林蛙油水溶性蛋白口服液在乙醇诱导氧化损伤模型小鼠体内的抗氧化实验及结果:
雄性昆明小鼠 60 只,随机分成 6 组,每组 10 只,即空白对照组、 模型对照组、阳性对照组、0.3、3.3、10.0 mL/(kg.d)林蛙油口服液受试组。空白对照组和模型对照组灌胃给予生理盐水,阳性对照组灌胃给予200 mg/(kg.d) 维生素C(VC),其他剂量组每日给予林蛙油口服液,连续喂养30天。最后一天,除空白组外,其他受试组按照 12 mL/kg 一次性灌胃给予50℅乙醇造成氧化损伤模型。造模6小时后,用氯仿麻醉所有实验动物,取血1 ml用于丙二醛(MDA)和超氧化物歧化酶(SOD)的测定。断颈处死所有实验动物,迅速取出肝脏,用于谷胱甘肽(GSH)和蛋白质羰基(PC)的测定。
实验结果如表1所示,结果表明,模型对照组与空白组对照组相比,小鼠血清中抗氧化酶SOD的活性下降(P < 0.01),抗氧化物质GSH含量下降(P < 0.01),脂质氧化产物MDA和PC的含量升高(P < 0.01),说明乙醇诱导氧化损伤模型造模成功。
三个受试组与模型对照组相比,SOD活力和GSH含量随林蛙油口服液剂量的提高而升高,MDA含量与PC含量随林蛙油口服液剂量的提高而降低。其中,中剂量组(3.3 mL/(kg.d))和高剂量组(10.0 mL/(kg.d))的MDA、SOD、GSH、PC与模型对照组相比具有极显著性差异(P < 0.01);低剂量组(0.3 mL/(kg.d))的MDA、GSH和PC含量与模型对照组相比有极显著差异(P < 0.01),SOD有显著差异(P < 0.05)。与阳性药对照组VC相比,高剂量林蛙油口服液(10.0 mL/(kg.d))各方面抗氧化能力均优于VC。
因此,中、高剂量(3.3 mL/(kg.d)、10.0 mL/(kg.d))的林蛙油口服液在提高抗氧化酶SOD活力,提高抗氧化物质GSH含量,降低脂质氧化产物MDA和PC含量方面,显示出显著的抗氧化能力,其中10.0 mL/(kg.d) 高剂量组同时优于阳性对照组。
Claims (6)
1.一种林蛙油水溶性蛋白口服液,其特征在于:每1000mL所述口服液含有以下重量的各组分:林蛙油水溶性蛋白100~50g,矫味剂12.5~5g,防腐剂1~2g;所述林蛙油水溶性蛋白的制备包括:1)林蛙油水溶性总蛋白的提取和2)林蛙油水溶性蛋白的纯化;所述1)林蛙油水溶性总蛋白的提取的具体步骤为:取林蛙油,加入 pH 6.0 ~ 7.0 的5~10倍量水溶液中搅拌提取3~5 h,压滤,残渣重复提取,合并提取液,进行第一次离心处理,取上清液,经中空纤维柱膜过滤,滤液用65%~70%硫酸铵沉淀6~12 h,进行第二次离心处理,将沉淀置0~10℃蒸馏水透析,至透析液没有沉淀产生,进行第三次离心处理,得含有林蛙油水溶性总蛋白的上清液;所述2)林蛙油水溶性蛋白的纯化的具体步骤为:将1)中所得含有林蛙油水溶性总蛋白的上清液中加入Amberlite CG50树脂,于20~25℃搅拌吸附2~5 h,倾去上层液体,所述树脂用蒸馏水洗涤后上柱,用0.2-0.4 mol/L磷酸氢二钾-0.1-0.3 mol/L氯化钾混合液洗脱,流速8 mL/10 min,洗脱液用蒸馏水透析去离子后真空冷冻干燥,得纯化后的林蛙油水溶性蛋白;按上述组分的重量,取林蛙油水溶性蛋白加入到纯化水中,180~220 r/min 搅拌至溶解,控制温度10~30℃,再分别加入矫味剂、防腐剂于180~220 r/min转速下搅拌均匀后,罐装瞬时灭菌,装瓶、封口。
2.根据权利要求1所述的林蛙油水溶性蛋白口服液,其特征在于:所述矫味剂为蔗糖、木糖醇、三氯蔗糖、橙皮糖浆、枸橼糖浆、樱桃糖浆、甘草糖浆、桂皮糖浆、甜菊苷其中一种或几种的混合物。
3.根据权利要求1所述的林蛙油水溶性蛋白口服液,其特征在于:所述矫味剂为木糖醇或木糖醇与蔗糖、三氯蔗糖、橙皮糖浆、枸橼糖浆、樱桃糖浆、甘草糖浆、桂皮糖浆、甜菊苷中其中一种或几种混合物。
4.根据权利要求1所述的林蛙油水溶性蛋白口服液,其特征在于:所述矫味剂为甘草糖浆或甘草糖浆与木糖醇、蔗糖、三氯蔗糖、橙皮糖浆、枸橼糖浆、樱桃糖浆、桂皮糖浆、甜菊苷中其中一种或几种混合物。
5.根据权利要求1所述的林蛙油水溶性蛋白口服液,其特征在于:所述防腐剂为苯甲酸、苯甲酸钠、山梨酸、山梨酸钾、丙酸钙、尼泊金甲酯、尼泊金乙酯中一种或两种。
6.权利要求1所述林蛙油水溶性蛋白口服液在制备抗氧化保健食品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510985270.7A CN105497868B (zh) | 2015-12-25 | 2015-12-25 | 一种林蛙油水溶性蛋白口服液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510985270.7A CN105497868B (zh) | 2015-12-25 | 2015-12-25 | 一种林蛙油水溶性蛋白口服液及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105497868A CN105497868A (zh) | 2016-04-20 |
CN105497868B true CN105497868B (zh) | 2019-01-01 |
Family
ID=55706417
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510985270.7A Active CN105497868B (zh) | 2015-12-25 | 2015-12-25 | 一种林蛙油水溶性蛋白口服液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105497868B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106901367A (zh) * | 2017-03-14 | 2017-06-30 | 张勇 | 一种平衡血糖的组合物以及制备方法和用途 |
CN110042138B (zh) * | 2019-04-10 | 2020-12-29 | 常熟理工学院 | 一种林蛙油抗氧化肽组分的制备方法及其分离方法与用途 |
CN110438186A (zh) * | 2019-07-31 | 2019-11-12 | 杭州妇帮医疗科技有限公司 | 一种制备林蛙卵中多肽成分的方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1076857A (zh) * | 1992-04-01 | 1993-10-06 | 吉林省柳河制药厂 | 一种蛤蟆油口服液的制造方法 |
CN1313094A (zh) * | 2000-03-09 | 2001-09-19 | 马术村 | 一种滋补强体口服液 |
CN104705633A (zh) * | 2013-12-11 | 2015-06-17 | 尚庆光 | 一种口服液保健品加工工艺 |
-
2015
- 2015-12-25 CN CN201510985270.7A patent/CN105497868B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1076857A (zh) * | 1992-04-01 | 1993-10-06 | 吉林省柳河制药厂 | 一种蛤蟆油口服液的制造方法 |
CN1313094A (zh) * | 2000-03-09 | 2001-09-19 | 马术村 | 一种滋补强体口服液 |
CN104705633A (zh) * | 2013-12-11 | 2015-06-17 | 尚庆光 | 一种口服液保健品加工工艺 |
Non-Patent Citations (2)
Title |
---|
林蛙油抗氧化组分筛选及水溶性蛋白抗氧化肽的制备;张馨月;《食品科技》;20140531;第39卷(第5期);摘要,第218页1.2.2部分,第219页图2,第220页讨论部分 |
蛤蟆油水溶性总蛋白对小鼠耐缺氧及抗氧化能力的影响;吴运明等;《食品科技》;20120430;第37卷(第4期);47-50页 |
Also Published As
Publication number | Publication date |
---|---|
CN105497868A (zh) | 2016-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4669920B2 (ja) | 血糖上昇抑制且つ血圧上昇抑制作用を有する機能性素材 | |
CN110042138B (zh) | 一种林蛙油抗氧化肽组分的制备方法及其分离方法与用途 | |
CN105497868B (zh) | 一种林蛙油水溶性蛋白口服液及其制备方法 | |
CN102504039A (zh) | 一种黑色玉米须多糖的提取工艺 | |
CN106565838A (zh) | 一种稳定性好的藻蓝蛋白及其制备方法、组合物和应用 | |
CN109601795A (zh) | 以赶黄草为主要原料的组合物解酒饮料及其制备方法 | |
CN101664180B (zh) | 一种具有保健功效的营养复合剂及其制备方法 | |
CN109349467B (zh) | 大鲵饮品 | |
JP2001178429A (ja) | 機能性抗糖尿飲料 | |
KR20020092082A (ko) | 자양강장제 조성물 | |
KR100506622B1 (ko) | 건강식품 조성물 및 그의 제조방법 | |
CN114982853B (zh) | 化橘红-异黄酮肽凝胶软糖及其制备方法 | |
CN103349079B (zh) | 一种美味牛肝菌功能性乳饮料的生产方法 | |
KR100318223B1 (ko) | 페피노 추출물을 함유하는 혈중알콜농도 저하용 조성물 및 그 제조방법 | |
CN105713787B (zh) | 一种护肝型藏红花葛根黄酒的制备方法 | |
CN106937923A (zh) | 灵芝花粉护肤防衰霜 | |
CN108077512A (zh) | 辣木叶降糖茶及其制备方法 | |
CN110897157A (zh) | 一种保健制剂、制备工艺及用途 | |
CN111588040A (zh) | 抗疲劳美白保湿解酒的保健配方 | |
JP2001192342A (ja) | ステビア濃縮液剤および成熟ざくろ混合物の製造方法 | |
CN110038090A (zh) | 一种具有抗痛风作用的复合芹菜籽油自乳化软胶囊及其制备方法 | |
CN101530210B (zh) | 一种养生酒 | |
CN104687051A (zh) | 一种海洋生物营养液及其制备方法 | |
CN109123541A (zh) | 对化学肝损伤有辅助保护功能的果冻及其制备方法 | |
CN110218754A (zh) | 一种抗氧化肽的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |